Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib for EGFR-mutated NSCLC with Brain or Leptomeningeal Metastases
NCT04233021Phase 2Completed
- Sponsor
- IFCT
- Start
- Jul 2020
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in EGFR-mutated non-small cell lung cancer, sponsored by IFCT. Primary endpoint: Objective Response Rate at 6 months. Started Jul 2020; status: completed.
02
Drugs
03
Conditions
EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on NCT04233021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04233021.